Celentyx Enters Into Agreement With Meiji Seika Kaisha, Ltd. To Discover New Development Paths For Meiji Drug Candidates Using Celentyx's Novel Clinical Indication Profiling(TM)
8/24/2009 11:54:55 AM
More...
|
Amalyte and Meiji Seika Kaisha, Ltd. Enter Into a License, Development and Commercialization Agreement on AM3301 and a Novel Class of Anti-Inflammatory Compounds
6/8/2009 9:48:28 AM
More...
|
ACADIA Pharmaceuticals, Inc. (ACAD) And Meiji Seika Kaisha, Ltd. Form Collaboration to Develop and Commercialize a New Class of Pro-Cognitive Schizophrenia Drugs
3/25/2009 10:18:42 AM
More...
|
Symphogen A/S and Meiji Seika Kaisha, Ltd. Achieve Milestone in Discovery Collaboration for Recombinant Polyclonal Antibody, Sym006
12/4/2008 10:21:24 AM
More...
|
Symphogen A/S And Meiji Seika Kaisha, Ltd. Enter Agreement For Recombinant Polyclonal Antibody Product
12/11/2006 12:50:10 PM
More...
|
Cerexa, Inc. Expands Portfolio Of Novel Anti-Infective Therapies Through In-Licensing Agreement With Meiji Seika Kaisha, Ltd.
11/1/2006 12:24:23 PM
More...
|
MediciNova, Inc. Announces The Acquisition Of Two Novel Antithrombotic Agents From Meiji Seika Kaisha, Ltd.
11/1/2006 11:18:37 AM
More...
|
Meiji Seika Kaisha, Ltd. And Solvay Seiyaku Obtain Additional Approval For Fluvoxamine Maleate
10/19/2005 5:13:22 PM
More...
|
Nippon Organon KK Licenses Antidepressant To Meiji Seika Kaisha, Ltd.
10/19/2005 5:11:19 PM
More...
|
Meiji Seika Kaisha, Ltd. Subsidiary Receives Sales Approval For "MEIACT" In Spain
10/19/2005 5:11:05 PM
More...
|
|